Impact
Rgenix has multiple cancer therapies in development impacting several prevalent cancer types.
Our proprietary RNA-based target discovery platform identifies novel cancer targets that are largely invisible to DNA sequencing technology. Originally developed by Rgenix’s scientific co-founders at The Rockefeller University, the platform is now exclusively licensed to Rgenix.
Rgenix’s product pipeline addresses cancers diagnosed in more than 500,000 patients annually in the US, including drug-resistant cancer types. These cancers result in more than 250,000 deaths per year in America, with 5-year survival rates often as low as 10%-20% for patients with metastatic disease.
We have exclusive worldwide rights to all of the programs in our pipeline and our lead program has obtained three orphan drug designations for several solid tumor types.
Rgenix Oncology Pipeline
Current status of programs
| Preclinical Stage | Phase 1a | Phase 1b/2 |
*RGX-104 + pembrolizumab + carboplatin/pemetrexed
Pipeline
RGX-104
RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
Pipeline
RGX-202
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancer.
Pipeline
RGX-019
RGX-019 is a monoclonal antibody that targets a key pathway that drives tumor progression and metastasis of several cancer types, including triple-negative breast cancer.